2016 -- S 2946 | |
======== | |
LC005939 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2016 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS - UNIFORMED CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Senator Louis P. DiPalma | |
Date Introduced: May 10, 2016 | |
Referred To: Senate Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 21-28-3.32 of the General Laws in Chapter 21-28 entitled "Uniform |
2 | Controlled Substances Act" is hereby amended to read as follows: |
3 | 21-28-3.32. Electronic prescription database. -- (a) The information contained in any |
4 | prescription drug monitoring database maintained by the department of health pursuant to § 21- |
5 | 28-3.18 of this chapter shall be disclosed only: |
6 | (1) To a practitioner who certifies that the requested information is for the purpose of |
7 | evaluating the need for, or providing medical treatment to, a current patient to whom the |
8 | practitioner is prescribing or considering prescribing a controlled substance; |
9 | (2) To a pharmacist who certifies that the requested information is for a current client to |
10 | whom the pharmacist is dispensing, or considering dispensing, a controlled substance; |
11 | (3) To an authorized designee of the practitioner and/or pharmacist to consult the |
12 | prescription drug monitoring database on the practitioner's and/or pharmacist's behalf, provided |
13 | that: |
14 | (i) The designee so authorized is employed by the same professional practice or |
15 | pharmacy; |
16 | (ii) The practitioner or pharmacist takes reasonable steps to ensure that such designee is |
17 | sufficiently competent in the use of the database; |
18 | (iii) The practitioner or pharmacist remains responsible for ensuring that access to the |
19 | database by the designee is limited to authorized purposes as provided for in subsections (a)(1) |
| |
1 | and (a)(2) of this section; |
2 | (iv) The practitioner or pharmacist remains responsible for ensuring access to the |
3 | database by the designee occurs in a manner that protects the confidentiality of information |
4 | obtained from the database and remains responsible for any breach of confidentiality; |
5 | (v) The practitioner or pharmacist terminates the designee's access to the database at the |
6 | termination of the designee's employment; and |
7 | (vi) The ultimate decision as to whether or not to prescribe or dispense a controlled |
8 | substance remains with the practitioner or pharmacist and is reasonably informed by the relevant |
9 | controlled substance history information obtained from the database. |
10 | (4) Pursuant to a valid search warrant based on probable cause to believe a violation of |
11 | federal or state criminal law has occurred and that specified information contained in the database |
12 | would assist in the investigation of the crime; |
13 | (5) To a patient who requests his or her own prescription information, or the parent or |
14 | legal guardian of a minor child who requests the minor child's prescription information; |
15 | (6) To a health professional regulatory board that documents, in writing, that the |
16 | requested information is necessary for an investigation related to licensure, renewal, or |
17 | disciplinary action involving the applicant, licensee, or registrant to whom the requested |
18 | information pertains; |
19 | (7) To any vendor or contractor with whom the department has contracted, pursuant to |
20 | state purchasing law and regulations in the contracting of vendors, to establish or maintain the |
21 | electronic system of the prescription drug monitoring database; or |
22 | (8) To public or private entities for statistical, research, or educational purposes, after |
23 | removing the patient and prescriber information that could be used to identify individual patients. |
24 | This shall not include entities receiving a waiver from the institutional review board. |
25 | (b) Information stored in the prescription drug monitoring database shall include only the |
26 | following: |
27 | (1) Patient's first and last name, and/or patient identification number; provided, however, |
28 | the patient's social security number shall not be recorded in whole or in part, patient sex, patient |
29 | date of birth, and patient address; |
30 | (2) Prescribing practitioner's name and drug enforcement administration prescriber |
31 | information number; |
32 | (3) Prescribing practitioner's office or hospital contact information; |
33 | (4) Prescription name, prescription number, prescription species code, national drug code |
34 | number, prescription dosage, prescription quantity, days' supply, new-refill code, number of |
| LC005939 - Page 2 of 6 |
1 | refills authorized, date the prescription was written, date the prescription was filled, payment |
2 | type; provided, however, no credit card number shall be recorded in whole or in part; and |
3 | (5) The drug enforcement administration pharmacy number of the pharmacy filling the |
4 | prescription. |
5 | (c) The department shall disclose any information relating to a patient maintained in the |
6 | prescription drug monitoring database to that patient, at no cost to the patient, within thirty (30) |
7 | business days after the department receives a written request from the patient for the information. |
8 | This information shall include the records maintained by the department pursuant to subsection |
9 | (e). Notwithstanding the above, the department may, at the request of the law enforcement |
10 | agency, withhold for up to sixty (60) days following the conclusion of a law enforcement |
11 | investigation, the disclosure to the patient that information has been obtained pursuant to |
12 | subdivision (a)(3). |
13 | (d) A patient may request, from the dispensing pharmacy, correction of any inaccurate |
14 | information contained within the prescription drug monitoring database in accordance with the |
15 | procedure specified by § 5-37.3-5(c). |
16 | (e) The department shall, for the period of time that prescription information is |
17 | maintained, maintain records of the information disclosed through the prescription drug |
18 | monitoring database, including, but not limited to: |
19 | (1) The identity of each person who requests or receives information from the |
20 | prescription drug monitoring database and the organization, if any, the person represents; |
21 | (2) The information released to each person or organization and the basis for its release |
22 | under subsection (a); and |
23 | (3) The dates the information was requested and provided. |
24 | (f) Prescription information contained within the prescription drug monitoring database |
25 | shall be removed no later than five (5) years from the date the information is entered into the |
26 | database. Records in existence prior to the enactment of this section shall be removed no later |
27 | than ten (10) years from the date the information is entered into the database. |
28 | (g) The department shall promptly notify any affected individual of an improper |
29 | disclosure of information from the prescription drug monitoring database or a breach in the |
30 | security of the prescription drug monitoring database that poses a significant risk of disclosure of |
31 | patient information to an unauthorized individual. |
32 | (h) At the time of signing a prescription that is required by the department to be entered |
33 | into the prescription drug monitoring database, the prescribing practitioner shall inform the |
34 | patient in writing of the existence of the prescription drug monitoring database, the patient's right |
| LC005939 - Page 3 of 6 |
1 | to access their own prescription information, and the name and contact information of the agency |
2 | operating the program. |
3 | (i) No person shall access information in the prescription monitoring database except to |
4 | the extent and for the purposes authorized by subsection (a). |
5 | (j) In any civil action allowing a violation of this chapter, the court may award damages, |
6 | including punitive damages, and reasonable attorneys' fees and costs to a prevailing plaintiff, and |
7 | injunctive and any other appropriate relief. |
8 | (k) Any pharmacist who, in his or her professional judgment, refuses to fill a prescription |
9 | based on information contained within the prescription drug monitoring database shall inform the |
10 | prescribing physician within twenty-four (24) hours. |
11 | (l) All practitioners shall, as a condition of the initial registration or renewal of the |
12 | practitioner's authority to prescribe controlled substances, register with the prescription drug |
13 | monitoring database maintained by the department of health. |
14 | (m) The department shall seek federal funding to improve the usefulness and value of the |
15 | prescription drug monitoring database program by increasing its analytical functionality, |
16 | timeliness, and scope, pursuant to the following: |
17 | (1) Utilizing data from additional data sources as permissible under state and federal |
18 | statutes; and |
19 | (2) Analyzing information submitted to the prescription drug monitoring database to |
20 | ensure that prescription data collected from dispensing pharmacists is readily accessible for a |
21 | given patient; to identify unusual or aberrant patterns of prescribing, dispensing or receiving |
22 | controlled substances; and to generate an automatic alert when such patterns arise. |
23 | (3) Developing regulations to ensure that prescription drug monitoring analyses are |
24 | updated and disseminated regularly to appropriate officials and that summary reports are provided |
25 | to the general assembly at least annually. In the development of said regulations, the department |
26 | may include any of the following analytical functions, within the boundaries of patient |
27 | confidentiality rights under state and federal law: |
28 | (i) Consolidate raw prescription data collected from dispensing pharmacists into a single |
29 | view of all prescriptions filled for a given patient; |
30 | (ii) Identify unusual or aberrant patterns of prescribing controlled substances, by relevant |
31 | prescriber attributes, and generate an automatic alert when such patterns arise; |
32 | (iii) Identify unusual or aberrant patterns of receiving prescriptions for controlled |
33 | substances, by relevant patient attributes, and generate an automatic alert when such patterns |
34 | arise; |
| LC005939 - Page 4 of 6 |
1 | (iv) Identify unusual or aberrant patterns of dispensing controlled substances, by relevant |
2 | dispenser attributes, and generate an automatic alert when such patterns arise; and |
3 | (v) Identify and visually display linkages among prescribers, patients, and dispensers that |
4 | can be used to detect any collusive behaviors. |
5 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC005939 | |
======== | |
| LC005939 - Page 5 of 6 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS - UNIFORMED CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would improve the usefulness and value of the prescription drug monitoring |
2 | database program by adding analytical functions, requiring program updates at least weekly, and |
3 | incorporating data from similar programs in other states. |
4 | This act would take effect upon passage. |
======== | |
LC005939 | |
======== | |
| LC005939 - Page 6 of 6 |